Spark Investment Management LLC bought a new position in OncoCyte Corp (NYSEAMERICAN:OCX) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 40,300 shares of the biotechnology company’s stock, valued at approximately $159,000.
Other institutional investors have also recently made changes to their positions in the company. Perkins Capital Management Inc. purchased a new position in shares of OncoCyte during the first quarter valued at $99,000. Virtu Financial LLC purchased a new position in shares of OncoCyte during the first quarter valued at $114,000. Vanguard Group Inc increased its stake in shares of OncoCyte by 3.8% during the third quarter. Vanguard Group Inc now owns 410,275 shares of the biotechnology company’s stock valued at $1,026,000 after buying an additional 15,115 shares during the period. Finally, Emerald Mutual Fund Advisers Trust purchased a new position in shares of OncoCyte during the first quarter valued at $9,836,000.
OCX has been the topic of several research reports. Chardan Capital restated a “buy” rating and set a $8.00 price target on shares of OncoCyte in a research note on Tuesday, April 2nd. Lake Street Capital raised their price objective on OncoCyte from $4.00 to $7.00 and gave the company a “buy” rating in a research report on Tuesday, January 29th. Janney Montgomery Scott raised OncoCyte from a “neutral” rating to a “buy” rating in a research report on Tuesday, January 29th. Zacks Investment Research raised OncoCyte from a “hold” rating to a “buy” rating and set a $2.00 price objective on the stock in a research report on Friday, January 25th. Finally, Piper Jaffray Companies started coverage on OncoCyte in a research report on Wednesday, February 13th. They set an “overweight” rating and a $6.00 price objective on the stock. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. OncoCyte currently has a consensus rating of “Buy” and a consensus target price of $6.00.
Shares of OCX stock opened at $4.48 on Friday. OncoCyte Corp has a 1-year low of $1.16 and a 1-year high of $6.92.
OncoCyte (NYSEAMERICAN:OCX) last issued its quarterly earnings data on Tuesday, May 14th. The biotechnology company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01.
OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer.
Recommended Story: What is a conference call?
Want to see what other hedge funds are holding OCX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OncoCyte Corp (NYSEAMERICAN:OCX).
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.